The Rahman Lab at King’s College London focuses on translational drug discovery to address urgent medical needs in infection, cancer, tuberculosis, and inflammation. We have pioneered efflux-resistant antimicrobials, novel anticancer payloads and PROTACs, and heme oxygenase-1 inhibitors for immunotherapy.
With 23 patents and three spin-out companies, our group translates innovation into real-world therapies. We collaborate widely with academic and industry partners across the UK, Europe, and the USA to deliver novel, impactful medicines that combat antimicrobial resistance, advance anticancer therapy and improve patient outcomes.
Dr Miraz Rahman is a Professor of Medicinal Chemistry in School of Cancer & Pharmaceutical Sciences, King’s College London.
Postdoctoral fellows
PhD Students
Visual Abstracts of Our Ongoing Projects
